The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Clairity Inc. received FDA De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025—propelling a new era of precision medicine in breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

People across Croatia gain access to advanced radiosurgery close to home at UPMC Hillman Cancer Center in Zabok

UPMC Hillman Cancer Center at Zabok General Hospital in Croatia is expanding access to the most advanced radiosurgery services for people across the country with the introduction of the Varian TrueBeam stereotactic body radiation therapy and stereotactic radiosurgery system. The new system delivers radiosurgery treatment with pinpoint accuracy and image-guided precision in a shorter amount of time than current conventional treatments.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account